Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 891 across all filing types
Latest filing 2026-01-15 Earnings Release
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Sobi's 2025 annual revenue and adjusted EBITA margin exceed previous outlook
Earnings Release Classification · 100% confidence The document is a press release announcing preliminary financial results (revenue and adjusted EBITA margin) for the full year 2025, which exceeded the company's previous outlook. It explicitly states that the full report will be announced on a later date (5 February 2026). Since this is an initial announcement of key financial highlights rather than the full report itself, it falls under the Earnings Release (ER) category. FY 2025
2026-01-15 English
Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data
Regulatory Filings Classification · 95% confidence The document is a press release from Sobi (Swedish Orphan Biovitrum) announcing topline results from a Phase 2a clinical trial (EMBRACE) for their drug Gamifant. It details the study's purpose, methodology, and outcomes, and explicitly states it is being published in accordance with the EU Market Abuse Regulation. As it is an announcement of clinical trial results rather than a full financial report, a transcript, or a regulatory filing of a different nature, it falls under the category of a general regulatory announcement or press release regarding company activities.
2026-01-07 Swedish
Sobi vidareutvecklar Gamifant® (emapalumab) vid gammainterferon-driven sepsis (IDS) baserat på topline-data från EMBRACE
Regulatory Filings Classification · 95% confidence The document is a press release from Sobi (Swedish Orphan Biovitrum) announcing topline results from a Phase 2a clinical trial (EMBRACE) for their drug Gamifant. It details the study's purpose, methodology, and outcomes, and explicitly states it is being published in accordance with the EU Market Abuse Regulation. As it is an announcement of clinical trial results rather than a full financial report, a transcript, or a regulatory filing of a different nature, it falls under the category of a general regulatory announcement or press release regarding company activities.
2026-01-07 Swedish
Sobi förvärvar Arthrosi Therapeutics och stärker sin pipeline med potentiell behandling av gikt
M&A Activity Classification · 100% confidence The document is a press release announcing that Sobi has entered into a definitive agreement to acquire Arthrosi Therapeutics. It details the transaction terms, the strategic rationale, and provides information about the target company and the drug candidate. This is a classic M&A announcement, which falls under the 'M&A Activity' category.
2025-12-13 Swedish
Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
M&A Activity Classification · 100% confidence The document is a press release announcing a definitive agreement for Sobi to acquire Arthrosi Therapeutics. It details the transaction terms, strategic rationale, and provides an invitation to a conference call. This fits the definition of M&A activity (TAR) as it concerns a merger/acquisition proposal and its associated details.
2025-12-13 English
Förändring i Sobis styrelse
Board/Management Information Classification · 100% confidence The document is a press release announcing the resignation of a board member (Helena Saxon) from the company Sobi. This falls directly under the category of announcements regarding changes in the company's board of directors.
2025-10-21 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.